RhumbLine Advisers
FSTX

RhumbLine Advisers’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

RhumbLine Advisers’s Portfolio FSTX Stock Details FSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-4,384
Closed -$184K – 3028
2019
Q1 		$184K Buy
4,384
+191
+5% +$8.05K ﹤0.01% 2766
2018
Q4 		$174K Buy
4,193
+1,656
+65% +$74.5K ﹤0.01% 2775
2018
Q3 		$122K Buy
+2,537
New +$127K ﹤0.01% 2841

Other funds holding FSTX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TA
Tiedemann Advisors New York $2.33B AUM 15.56% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RhumbLine Advisers's FSTX Position: Q2 2019 in Review

RhumbLine Advisers sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q2 2019, closing a stake of 4,384 shares — an estimated $184K sold.

RhumbLine Advisers first reported a position in FSTX in Q3 2018 and held it in 3 quarters. The position peaked at $184K in Q1 2019. 50 funds tracked by Wall St. Rank hold FSTX as of Q2 2019.

  • RhumbLine Advisers reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • RhumbLine Advisers sold 4,384 F-star Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $184K.
  • RhumbLine Advisers first reported a position in F-star Therapeutics, Inc. Common Stock in Q3 2018 and held it in 3 quarters.
  • RhumbLine Advisers's F-star Therapeutics, Inc. Common Stock position peaked at $184K in Q1 2019.
  • 50 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q2 2019.

Based on RhumbLine Advisers's 13F filing for Q2 2019, filed 14 Aug 2019.